摘要
目的探讨^(18)F-氟代脱氧葡萄糖(^(18)F-FDG)正电子发射计算机断层显像(PET)/CT在食管癌放疗靶区勾画中的应用。方法选取80例食管癌患者,均采用增强CT和PET/CT检查,比较增强CT检查和PET/CT检查诊断食管癌患者的TNM分期、大体肿瘤靶区(GTV)和检查费用。结果病理学检查结果显示,80例食管癌患者TNM分期中,T_(1)、T_(2)、T_(3)、T_(4)分期分别为6、42、24、8例,N_(1)、N_(2)、N_(3)分期分别为4、34、42例,M_(0)、M_(1)分期分别18、62例。PET/CT检查诊断食管癌患者T、N、M分期的准确度分别为95.00%、97.50%、95.00%,分别高于CT检查的57.50%、70.00%、65.00%(P﹤0.05)。PET/CT检查在鳞状细胞癌、小细胞癌、腺癌勾画靶区中的GTV均明显小于CT检查(P﹤0.05)。PET/CT检查的费用高于增强CT检查(P﹤0.05)。结论^(18)F-FDG PET/CT检查能够明确诊断食管癌患者的TNM分期,在一定程度上提高放疗靶区勾画的准确度,临床应用价值较高。
Objective To explore the application of ^(18)F-fluorodeoxyglucose(^(18)F-FDG)position emission tomography(PET)/CT in delineating the target volume of esophageal cancer radiotherapy.Method A total of 80 patients with esophageal cancer were selected,and contrast-enhanced CT and PET/CT were used to compare the TNM staging,gross tumor volume(GTV)and examination costs of patients with esophageal cancer.Result Pathological examination showed that among the TNM stages of 80 esophageal cancer patients,T_(1),T_(2),T_(3) and T_(4) stages were 6,42,24 and 8 cases respectively,N_(1),N_(2) and N_(3) stages were 4,34 and 42 cases,and M_(0) and M_(1) stages were 18 and 62 cases,respectively.The accuracy of PET/CT in diagnosing T,N,and M staging in patients with esophageal cancer were 95.00%,97.50%,and 95.00%,respectively,which were higher than those of CT(57.50%,70.00%,and 65.00%)(P<0.05).The GTV of squamous cell carcinoma,small cell carcinoma and adenocarcinoma delineated by PET/CT were significantly lower than those of CT(P<0.05).The cost of PET/CT examination was higher than that of contrast-enhanced CT examination(P<0.05).Conclusion ^(18)F-FDG PET/CT can clearly diagnose the TNM staging of esophageal cancer patients,improve the accuracy of radiotherapy target delineation to a certain extent,and has high clinical application value.
作者
郑婷婷
尹信
张杨勇
ZHENG Tingting;YIN Xin;ZHANG Yangyong(Department of Nuclear Medicine,Xianyang Hospital of Yan’an University,Xianyang 712000,Shaanxi,China;Department of Radiotherapy,Xianyang Hospital of Yan’an University,Xianyang 712000,Shaanxi,China)
出处
《癌症进展》
2022年第8期809-812,共4页
Oncology Progress
